A 52-year-old man with hypertension and paroxysmal atrial fibrillation is being evaluated for antiarrhythmic therapy. His cardiologist is deciding between flecainide and amiodarone. Which feature best distinguishes flecainide (Class IC) from amiodarone (Class III)?

Explanation

## Distinguishing Class IC from Class III Antiarrhythmics ### Mechanism of Action: The Key Discriminator **Key Point:** The fundamental difference between Class IC (flecainide) and Class III (amiodarone) agents lies in their primary electrophysiological effect: | Feature | Class IC (Flecainide) | Class III (Amiodarone) | |---------|----------------------|----------------------| | **Primary action** | Sodium channel blockade | Potassium channel blockade | | **Effect on APD** | Minimal or no prolongation | Marked prolongation | | **QT interval** | Minimal change | Significant prolongation | | **Conduction velocity** | Markedly decreased | Mildly decreased | | **Refractory period** | Minimally increased | Markedly increased | ### Class IC Mechanism (Flecainide) 1. **Rapid sodium channel blockade** — flecainide binds tightly to Na^+^ channels, dramatically slowing phase 0 depolarization 2. **Minimal APD effect** — does NOT prolong the action potential duration 3. **Result:** Very narrow QRS complex widening with little QT change ### Class III Mechanism (Amiodarone) 1. **Potassium channel blockade** — inhibits outward K^+^ current during repolarization (phase 3) 2. **Marked APD prolongation** — extends the entire action potential duration 3. **Result:** Significant QT interval prolongation on ECG **High-Yield:** This distinction is **testable and clinically important** — flecainide's lack of APD prolongation makes it safer regarding torsades de pointes risk compared to Class III agents, though it carries its own proarrhythmic risk in structural heart disease. **Clinical Pearl:** Amiodarone is a "broad-spectrum" antiarrhythmic with properties of all four Vaughan-Williams classes, but its **dominant effect is Class III** (potassium channel blockade and APD prolongation). ### Why This Matters Clinically - **Flecainide** → narrow QRS, normal QT → risk of ventricular proarrhythmia in structural disease (CAST trial) - **Amiodarone** → wide QRS, prolonged QT → risk of torsades, but broader efficacy spectrum